<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://new.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Thu, 27 Aug 2026 11:36:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://new.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Form  POS AM     Scinai Immunotherapeutic             </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Scinai+Immunotherapeutic+++++++++++++/26987568.html</link>
   <description>si-local-file:///var/storage/secattach/20260827/26987568.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Scinai+Immunotherapeutic+++++++++++++/26987568.html</guid>
   <pubDate>Thu, 27 Aug 2026 11:36:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Form  POS AM     Scinai Immunotherapeutic             </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Scinai+Immunotherapeutic+++++++++++++/26987568.html</link>
   <description>si-local-file:///var/storage/secattach/20260827/26987568.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Scinai+Immunotherapeutic+++++++++++++/26987568.html</guid>
   <pubDate>Thu, 27 Aug 2026 11:36:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Form  6-K        Scinai Immunotherapeutic  For: Jun 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Jun+30/26977624.html</link>
   <description>si-local-file:///var/storage/secattach/20260826/26977624.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Jun+30/26977624.html</guid>
   <pubDate>Wed, 26 Aug 2026 08:14:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Form  6-K        Scinai Immunotherapeutic  For: Jun 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Jun+30/26977624.html</link>
   <description>si-local-file:///var/storage/secattach/20260826/26977624.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Jun+30/26977624.html</guid>
   <pubDate>Wed, 26 Aug 2026 08:14:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai posts H1 2026 results with wider operating loss, net gain</title>
   <link>http://www.streetinsider.com/Corporate+News/Scinai+posts+H1+2026+results+with+wider+operating+loss%2C+net+gain/26964137.html</link>
   <description>&lt;p&gt;Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported financial results for the six months ended June 30, 2026, showing revenue growth alongside a wider operating loss, according to a press release from the Jerusalem-based biopharmaceutical and contract development and manufacturing organization (CDMO) company.&lt;/p&gt;&lt;p&gt;Revenue rose to $949 thousand from $773 thousand in the same period of 2025, attributed primarily to the inclusion of revenues from the acquired Yavne operations. Cost of revenues increased to $3.3 million from $2.0 million, reflecting expanded costs following the acquisition. The gross loss widened to approximately $2.4 million from $1.3 million in the prior-year period.&lt;/p&gt;&lt;p&gt;The operating loss was</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Corporate+News/Scinai+posts+H1+2026+results+with+wider+operating+loss%2C+net+gain/26964137.html</guid>
   <pubDate>Mon, 24 Aug 2026 07:06:53 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Investor webinar scheduled for &lt;chron&gt;August 26, 2026&lt;/chron&gt; at &lt;chron&gt;11:00 a.m. EDT&lt;/chron&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 24, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ – &lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:SCNI&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt; &lt;/b&gt;(NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization (&quot;CDMO&quot;), today provided a corporate update and reported financial results for the six months ended &lt;chron&gt;June 30, 2026&lt;/chron&gt;.&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;div class=&quot;PRN_ImbeddedAssetReference&quot; id=&quot;DivAssetPlaceHolder2259&quot;&gt;&lt;p&gt;&lt;img src=&quot;https://mmx.prnewswire.com/media/MS1974077/Scinai-Webinar-Graphic.jpg?id=OA2904902&quot; title=&quot;Scinai Immunotherapeutics will host an investor webinar on August 26, 2026, to discuss recent company developments, financial performance and upcoming milestones.&quot; alt=&quot;Scinai Immunotherapeutics will host an investor webinar on August</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</guid>
   <pubDate>Mon, 24 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.F</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Investor webinar scheduled for &lt;chron&gt;August 26, 2026&lt;/chron&gt; at &lt;chron&gt;11:00 a.m. EDT&lt;/chron&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 24, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ – &lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:SCNI&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt; &lt;/b&gt;(NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization (&quot;CDMO&quot;), today provided a corporate update and reported financial results for the six months ended &lt;chron&gt;June 30, 2026&lt;/chron&gt;.&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;div class=&quot;PRN_ImbeddedAssetReference&quot; id=&quot;DivAssetPlaceHolder2259&quot;&gt;&lt;p&gt;&lt;img src=&quot;https://mmx.prnewswire.com/media/MS1974077/Scinai-Webinar-Graphic.jpg?id=OA2904902&quot; title=&quot;Scinai Immunotherapeutics will host an investor webinar on August 26, 2026, to discuss recent company developments, financial performance and upcoming milestones.&quot; alt=&quot;Scinai Immunotherapeutics will host an investor webinar on August</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</guid>
   <pubDate>Mon, 24 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.F</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Investor webinar scheduled for &lt;chron&gt;August 26, 2026&lt;/chron&gt; at &lt;chron&gt;11:00 a.m. EDT&lt;/chron&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 24, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ – &lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:SCNI&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt; &lt;/b&gt;(NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization (&quot;CDMO&quot;), today provided a corporate update and reported financial results for the six months ended &lt;chron&gt;June 30, 2026&lt;/chron&gt;.&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;div class=&quot;PRN_ImbeddedAssetReference&quot; id=&quot;DivAssetPlaceHolder2259&quot;&gt;&lt;p&gt;&lt;img src=&quot;https://mmx.prnewswire.com/media/MS1974077/Scinai-Webinar-Graphic.jpg?id=OA2904902&quot; title=&quot;Scinai Immunotherapeutics will host an investor webinar on August 26, 2026, to discuss recent company developments, financial performance and upcoming milestones.&quot; alt=&quot;Scinai Immunotherapeutics will host an investor webinar on August</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</guid>
   <pubDate>Mon, 24 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.F</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Investor webinar scheduled for &lt;chron&gt;August 26, 2026&lt;/chron&gt; at &lt;chron&gt;11:00 a.m. EDT&lt;/chron&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 24, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ – &lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:SCNI&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt; &lt;/b&gt;(NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization (&quot;CDMO&quot;), today provided a corporate update and reported financial results for the six months ended &lt;chron&gt;June 30, 2026&lt;/chron&gt;.&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;div class=&quot;PRN_ImbeddedAssetReference&quot; id=&quot;DivAssetPlaceHolder2259&quot;&gt;&lt;p&gt;&lt;img src=&quot;https://mmx.prnewswire.com/media/MS1974077/Scinai-Webinar-Graphic.jpg?id=OA2904902&quot; title=&quot;Scinai Immunotherapeutics will host an investor webinar on August 26, 2026, to discuss recent company developments, financial performance and upcoming milestones.&quot; alt=&quot;Scinai Immunotherapeutics will host an investor webinar on August</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</guid>
   <pubDate>Mon, 24 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.F</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum</title>
   <link>http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Investor webinar scheduled for &lt;chron&gt;August 26, 2026&lt;/chron&gt; at &lt;chron&gt;11:00 a.m. EDT&lt;/chron&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 24, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ – &lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:SCNI&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt; &lt;/b&gt;(NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization (&quot;CDMO&quot;), today provided a corporate update and reported financial results for the six months ended &lt;chron&gt;June 30, 2026&lt;/chron&gt;.&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;div class=&quot;PRN_ImbeddedAssetReference&quot; id=&quot;DivAssetPlaceHolder2259&quot;&gt;&lt;p&gt;&lt;img src=&quot;https://mmx.prnewswire.com/media/MS1974077/Scinai-Webinar-Graphic.jpg?id=OA2904902&quot; title=&quot;Scinai Immunotherapeutics will host an investor webinar on August 26, 2026, to discuss recent company developments, financial performance and upcoming milestones.&quot; alt=&quot;Scinai Immunotherapeutics will host an investor webinar on August</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</guid>
   <pubDate>Mon, 24 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.F</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum</title>
   <link>http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Investor webinar scheduled for &lt;chron&gt;August 26, 2026&lt;/chron&gt; at &lt;chron&gt;11:00 a.m. EDT&lt;/chron&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 24, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ – &lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:SCNI&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt; &lt;/b&gt;(NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization (&quot;CDMO&quot;), today provided a corporate update and reported financial results for the six months ended &lt;chron&gt;June 30, 2026&lt;/chron&gt;.&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;div class=&quot;PRN_ImbeddedAssetReference&quot; id=&quot;DivAssetPlaceHolder2259&quot;&gt;&lt;p&gt;&lt;img src=&quot;https://mmx.prnewswire.com/media/MS1974077/Scinai-Webinar-Graphic.jpg?id=OA2904902&quot; title=&quot;Scinai Immunotherapeutics will host an investor webinar on August 26, 2026, to discuss recent company developments, financial performance and upcoming milestones.&quot; alt=&quot;Scinai Immunotherapeutics will host an investor webinar on August</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</guid>
   <pubDate>Mon, 24 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.F</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum</title>
   <link>http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Investor webinar scheduled for &lt;chron&gt;August 26, 2026&lt;/chron&gt; at &lt;chron&gt;11:00 a.m. EDT&lt;/chron&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 24, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ – &lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:SCNI&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt; &lt;/b&gt;(NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization (&quot;CDMO&quot;), today provided a corporate update and reported financial results for the six months ended &lt;chron&gt;June 30, 2026&lt;/chron&gt;.&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;div class=&quot;PRN_ImbeddedAssetReference&quot; id=&quot;DivAssetPlaceHolder2259&quot;&gt;&lt;p&gt;&lt;img src=&quot;https://mmx.prnewswire.com/media/MS1974077/Scinai-Webinar-Graphic.jpg?id=OA2904902&quot; title=&quot;Scinai Immunotherapeutics will host an investor webinar on August 26, 2026, to discuss recent company developments, financial performance and upcoming milestones.&quot; alt=&quot;Scinai Immunotherapeutics will host an investor webinar on August</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</guid>
   <pubDate>Mon, 24 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.F</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum</title>
   <link>http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Investor webinar scheduled for &lt;chron&gt;August 26, 2026&lt;/chron&gt; at &lt;chron&gt;11:00 a.m. EDT&lt;/chron&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 24, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ – &lt;b&gt;&lt;span value=&quot;NASDAQ-NMS:SCNI&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt; &lt;/b&gt;(NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization (&quot;CDMO&quot;), today provided a corporate update and reported financial results for the six months ended &lt;chron&gt;June 30, 2026&lt;/chron&gt;.&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;div class=&quot;PRN_ImbeddedAssetReference&quot; id=&quot;DivAssetPlaceHolder2259&quot;&gt;&lt;p&gt;&lt;img src=&quot;https://mmx.prnewswire.com/media/MS1974077/Scinai-Webinar-Graphic.jpg?id=OA2904902&quot; title=&quot;Scinai Immunotherapeutics will host an investor webinar on August 26, 2026, to discuss recent company developments, financial performance and upcoming milestones.&quot; alt=&quot;Scinai Immunotherapeutics will host an investor webinar on August</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Half+2026+Corporate+Highlights+and+Results+with+Spotlight+on+Growing+CDMO+Momentum/26964065.html</guid>
   <pubDate>Mon, 24 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.F</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Form  6-K        Scinai Immunotherapeutic  For: Aug 19</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Aug+19/26948154.html</link>
   <description>si-local-file:///var/storage/secattach/20260819/26948154.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Aug+19/26948154.html</guid>
   <pubDate>Wed, 19 Aug 2026 09:25:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Form  6-K        Scinai Immunotherapeutic  For: Aug 19</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Aug+19/26948154.html</link>
   <description>si-local-file:///var/storage/secattach/20260819/26948154.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Aug+19/26948154.html</guid>
   <pubDate>Wed, 19 Aug 2026 09:25:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Form  424B3      Scinai Immunotherapeutic             </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Scinai+Immunotherapeutic+++++++++++++/26917199.html</link>
   <description>si-local-file:///var/storage/secattach/20260813/26917199.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Scinai+Immunotherapeutic+++++++++++++/26917199.html</guid>
   <pubDate>Thu, 13 Aug 2026 08:44:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Form  424B3      Scinai Immunotherapeutic             </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Scinai+Immunotherapeutic+++++++++++++/26917199.html</link>
   <description>si-local-file:///var/storage/secattach/20260813/26917199.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Scinai+Immunotherapeutic+++++++++++++/26917199.html</guid>
   <pubDate>Thu, 13 Aug 2026 08:44:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Form  424B3      Scinai Immunotherapeutic             </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Scinai+Immunotherapeutic+++++++++++++/26917199.html</link>
   <description>si-local-file:///var/storage/secattach/20260813/26917199.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Scinai+Immunotherapeutic+++++++++++++/26917199.html</guid>
   <pubDate>Thu, 13 Aug 2026 08:44:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;span value=&quot;Frankfurt:2F5&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt;&lt;/a&gt; (NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/cdmo&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span&gt;Scinai Biopharma Services Ltd&lt;/span&gt;&lt;/b&gt;&lt;/a&gt;&lt;b&gt;.&lt;/b&gt;, a contract development and manufacturing organization (CDMO), has appointed &lt;b&gt;Mr. Eran Kuratz as Head of &lt;span&gt;Supply Chain and Business Process Administration&lt;/span&gt;&lt;/b&gt;. Mr. Kuratz reports directly to Scinai Chief Executive Officer &lt;person&gt;Amir Reichman&lt;/person&gt;.&lt;/p&gt;
 </description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</guid>
   <pubDate>Mon, 10 Aug 2026 06:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50113769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50114101</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50204092</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00038724</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00624550</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.13798113</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;span value=&quot;Frankfurt:2F5&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt;&lt;/a&gt; (NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/cdmo&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span&gt;Scinai Biopharma Services Ltd&lt;/span&gt;&lt;/b&gt;&lt;/a&gt;&lt;b&gt;.&lt;/b&gt;, a contract development and manufacturing organization (CDMO), has appointed &lt;b&gt;Mr. Eran Kuratz as Head of &lt;span&gt;Supply Chain and Business Process Administration&lt;/span&gt;&lt;/b&gt;. Mr. Kuratz reports directly to Scinai Chief Executive Officer &lt;person&gt;Amir Reichman&lt;/person&gt;.&lt;/p&gt;
 </description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</guid>
   <pubDate>Mon, 10 Aug 2026 06:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50113769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50114101</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50204092</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00038724</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00624550</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.13798113</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;span value=&quot;Frankfurt:2F5&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt;&lt;/a&gt; (NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/cdmo&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span&gt;Scinai Biopharma Services Ltd&lt;/span&gt;&lt;/b&gt;&lt;/a&gt;&lt;b&gt;.&lt;/b&gt;, a contract development and manufacturing organization (CDMO), has appointed &lt;b&gt;Mr. Eran Kuratz as Head of &lt;span&gt;Supply Chain and Business Process Administration&lt;/span&gt;&lt;/b&gt;. Mr. Kuratz reports directly to Scinai Chief Executive Officer &lt;person&gt;Amir Reichman&lt;/person&gt;.&lt;/p&gt;
 </description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</guid>
   <pubDate>Mon, 10 Aug 2026 06:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50113769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50114101</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50204092</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00038724</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00624550</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.13798113</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;span value=&quot;Frankfurt:2F5&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt;&lt;/a&gt; (NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/cdmo&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span&gt;Scinai Biopharma Services Ltd&lt;/span&gt;&lt;/b&gt;&lt;/a&gt;&lt;b&gt;.&lt;/b&gt;, a contract development and manufacturing organization (CDMO), has appointed &lt;b&gt;Mr. Eran Kuratz as Head of &lt;span&gt;Supply Chain and Business Process Administration&lt;/span&gt;&lt;/b&gt;. Mr. Kuratz reports directly to Scinai Chief Executive Officer &lt;person&gt;Amir Reichman&lt;/person&gt;.&lt;/p&gt;
 </description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</guid>
   <pubDate>Mon, 10 Aug 2026 06:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50113769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50114101</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50204092</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00038724</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00624550</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.13798113</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;span value=&quot;Frankfurt:2F5&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt;&lt;/a&gt; (NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/cdmo&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span&gt;Scinai Biopharma Services Ltd&lt;/span&gt;&lt;/b&gt;&lt;/a&gt;&lt;b&gt;.&lt;/b&gt;, a contract development and manufacturing organization (CDMO), has appointed &lt;b&gt;Mr. Eran Kuratz as Head of &lt;span&gt;Supply Chain and Business Process Administration&lt;/span&gt;&lt;/b&gt;. Mr. Kuratz reports directly to Scinai Chief Executive Officer &lt;person&gt;Amir Reichman&lt;/person&gt;.&lt;/p&gt;
 </description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</guid>
   <pubDate>Mon, 10 Aug 2026 06:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50113769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50114101</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50204092</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00038724</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00624550</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.13798113</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;span value=&quot;Frankfurt:2F5&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt;&lt;/a&gt; (NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/cdmo&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span&gt;Scinai Biopharma Services Ltd&lt;/span&gt;&lt;/b&gt;&lt;/a&gt;&lt;b&gt;.&lt;/b&gt;, a contract development and manufacturing organization (CDMO), has appointed &lt;b&gt;Mr. Eran Kuratz as Head of &lt;span&gt;Supply Chain and Business Process Administration&lt;/span&gt;&lt;/b&gt;. Mr. Kuratz reports directly to Scinai Chief Executive Officer &lt;person&gt;Amir Reichman&lt;/person&gt;.&lt;/p&gt;
 </description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</guid>
   <pubDate>Mon, 10 Aug 2026 06:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50113769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50114101</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50204092</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00038724</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00624550</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.13798113</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
  <item>
   <title>Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration</title>
   <link>http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/il..jerusl&quot; idsrc=&quot;xmltag.org&quot; &gt;JERUSALEM&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;Aug. 10, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;span value=&quot;Frankfurt:2F5&quot; idsrc=&quot;xmltag.org&quot; &gt;Scinai Immunotherapeutics Ltd.&lt;/span&gt;&lt;/a&gt; (NASDAQ: SCNI) (&quot;Scinai&quot; or the &quot;Company&quot;), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, &lt;a target=&quot;_blank&quot; href=&quot;https://www.scinai.com/cdmo&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;&lt;b&gt;&lt;span&gt;Scinai Biopharma Services Ltd&lt;/span&gt;&lt;/b&gt;&lt;/a&gt;&lt;b&gt;.&lt;/b&gt;, a contract development and manufacturing organization (CDMO), has appointed &lt;b&gt;Mr. Eran Kuratz as Head of &lt;span&gt;Supply Chain and Business Process Administration&lt;/span&gt;&lt;/b&gt;. Mr. Kuratz reports directly to Scinai Chief Executive Officer &lt;person&gt;Amir Reichman&lt;/person&gt;.&lt;/p&gt;
 </description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Scinai+Strengthens+CDMO+Leadership+with+Appointment+of+Eran+Kuratz+as+Head+of+Supply+Chain+and+Business+Process+Administration/26893839.html</guid>
   <pubDate>Mon, 10 Aug 2026 06:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">2F5</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">2F5.MU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50113769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50114101</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50204092</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00038724</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00624550</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.05713057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.13798113</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SCNI</category>
   	  </item>
 </channel>
</rss>
